
Meet Cont®aFlu - a patent protected non-prescription remedy,
a safe and effective alternative to Tamiflu and Theraflu
Cont®aFlu is the first patent protected non-prescription product
for flu-like infections over the last 30+ years
The unique features of Cont®aFlu are:
-
It is based on Nobel Prize winning scientific discovery in innate immunity, that is has very solid scientific foundation and targets the mechanism of the disease
-
it is developed in full compliance with the principles of Evidence Based Medicine
-
it has the best possible IP protection: strong patents in the largest markets and a brilliant global trade mark
-
it is more effective for flu than any other product in this market niche
-
it can be positioned as the best option for people with chronic diseases, the population most vulnerable to flu complications and side effects of existing treatments
-
it can start off by winning patients' attention as a part of the family's first-aid kit for adults with chronic diseases
Cont®aFlu is just one step away from registration in the EU.
Cont®aFlu has all prerequisites to become the leader in over-the-counter (OTC) flu market niche thanks to its true novelty, efficacy, and an outstanding trade mark.
What's more, Cont®aFlu will also be able to compete with the best-selling OTC products owing to its therapeutic, regulatory and marketing profile.
Due to low manufacturing cost (<$0.70) Cont®aFlu can be affordable to patients in both high-income and middle-income countries.
Cont®aFlu is designed for health conscious people who prefer to treat flu with a safe and effective medication.
Cont®aFlu is destined to become a safe and effective, patent protected alternative to both Rx Tamiflu and OTC Theraflu-like products.
The IP package of Cont®aFlu is offered for acquisition to a company active in the OTC flu niche.
PRESS HERE to see the partnering proposal.
Project origin: EU (Belgium)
Press the button
to see the slide deck
Watch our video to see how Cont®aFlu works
The science
Cont®aFlu is based on a groundbreaking discovery in innate immunity and an original drug development platform:
-
It makes use of a very promising molecular target; earlier attempts of large pharma companies to use it in viral infections has failed
-
Its author has prior experience of developing 6 other successful OTC products for Russian market
-
The key studies were performed in USA and Belgium
Efficacy
In influenza and flu-like infections Cont®aFlu provides:
-
Shorter disease duration by at least 2 days
-
Lower disease severity by at least 30%
-
Alleviation of major symptoms seen within 24 hours